170 related articles for article (PubMed ID: 33851271)
41. Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage.
Keegan KA; Schupp CW; Chamie K; Hellenthal NJ; Evans CP; Koppie TM
J Urol; 2012 Aug; 188(2):391-7. PubMed ID: 22698625
[TBL] [Abstract][Full Text] [Related]
42. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
43. Renal sinus fat invasion in pT3a clear cell renal cell carcinoma affects outcomes of patients without nodal involvement or distant metastases.
Bertini R; Roscigno M; Freschi M; Strada E; Petralia G; Pasta A; Matloob R; Sozzi F; Da Pozzo L; Colombo R; Guazzoni G; Doglioni C; Montorsi F; Rigatti P
J Urol; 2009 May; 181(5):2027-32. PubMed ID: 19286201
[TBL] [Abstract][Full Text] [Related]
44. Surgical margin does not influence recurrence rate in pT1 clear cell renal cell carcinoma after partial nephrectomy: A multicenter study.
Kang HW; Lee SK; Kim WT; Yun SJ; Lee SC; Kim WJ; Hwang EC; Kang SH; Hong SH; Chung J; Kwon TG; Kim HH; Kwak C; Byun SS; Kim YJ;
J Surg Oncol; 2016 Jul; 114(1):70-4. PubMed ID: 27074886
[TBL] [Abstract][Full Text] [Related]
45. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy.
Itano NB; Blute ML; Spotts B; Zincke H
J Urol; 2000 Aug; 164(2):322-5. PubMed ID: 10893575
[TBL] [Abstract][Full Text] [Related]
46. Extent of lymph node dissection at nephrectomy affects cancer-specific survival and metastatic progression in specific sub-categories of patients with renal cell carcinoma (RCC).
Capitanio U; Suardi N; Matloob R; Roscigno M; Abdollah F; Di Trapani E; Moschini M; Gallina A; Salonia A; Briganti A; Montorsi F; Bertini R
BJU Int; 2014 Aug; 114(2):210-5. PubMed ID: 24854206
[TBL] [Abstract][Full Text] [Related]
47. [Analysis of clinicopathological features and prognosis in 68 patients with chromophobe renal cell carcinoma].
Huang JW; Zhang J; Dong BJ; Kong W; Niu SX; Chen YH; Xue W; Liu DM; Huang YR
Zhonghua Zhong Liu Za Zhi; 2012 Jul; 34(7):510-3. PubMed ID: 22967469
[TBL] [Abstract][Full Text] [Related]
48. Prognostic implications of sarcomatoid and rhabdoid differentiation in patients with grade 4 renal cell carcinoma.
Kara O; Maurice MJ; Zargar H; Malkoc E; Akca O; Andrade HS; Ramirez D; Caputo PA; Nelson RJ; Rini B; Kaouk JH
Int Urol Nephrol; 2016 Aug; 48(8):1253-1260. PubMed ID: 27215555
[TBL] [Abstract][Full Text] [Related]
49. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma.
Morgan TM; Mehra R; Tiemeny P; Wolf JS; Wu S; Sangale Z; Brawer M; Stone S; Wu CL; Feldman AS
Eur Urol; 2018 May; 73(5):763-769. PubMed ID: 29249291
[TBL] [Abstract][Full Text] [Related]
50. Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis.
Avulova S; Cheville JC; Lohse CM; Gupta S; Potretzke TA; Tsivian M; Thompson RH; Boorjian SA; Leibovich BC; Potretzke AM
Eur Urol; 2021 Feb; 79(2):225-231. PubMed ID: 33172723
[TBL] [Abstract][Full Text] [Related]
51. Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma.
Adamy A; Chong KT; Chade D; Costaras J; Russo G; Kaag MG; Bernstein M; Motzer RJ; Russo P
J Urol; 2011 Feb; 185(2):433-8. PubMed ID: 21167521
[TBL] [Abstract][Full Text] [Related]
52. Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma.
Paly JJ; Hallemeier CL; Biggs PJ; Niemierko A; Roeder F; Martínez-Monge R; Whitson J; Calvo FA; Fastner G; Sedlmayer F; Wong WW; Ellis RJ; Haddock MG; Choo R; Shipley WU; Zietman AL; Efstathiou JA
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):618-23. PubMed ID: 24411190
[TBL] [Abstract][Full Text] [Related]
53. Recurrence risk groups after nephrectomy for renal cell carcinoma.
Polanco Pujol L; Herranz Amo F; Caño Velasco J; Subirá Ríos D; Moralejo Gárate M; Hernández Cavieres J; Barbas Bernardos G; Bueno Chomón G; Rodríguez Fernández E; Hernández Fernández C
Actas Urol Esp (Engl Ed); 2020 Mar; 44(2):111-118. PubMed ID: 31836313
[TBL] [Abstract][Full Text] [Related]
54. [Postoperative prognosis of chromophobic renal cell carcinoma: comparative analysis of the multinational CORONA database].
May M; Zigeuner R; Aziz A; Cindolo L; Gilfrich C; Schips L; De Cobelli O; Rocco B; De Nunzio C; Tubaro A; Coman I; Feciche B; Truss M; Hoschke B; Dalpiaz O; Stoltze A; Fenske F; Fritsche HM; Chromecki T; Lebentrau S; Figenshau RS; Madison K; Sánchez-Chapado M; Del Carmen Santiago Martin M; Salzano L; Lotrecchiano G; Joniau S; Waidelich R; Stief CG; Brookman-May S; ;
Urologe A; 2014 Feb; 53(2):228-35. PubMed ID: 23836364
[TBL] [Abstract][Full Text] [Related]
55. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent.
Merrill MM; Wood CG; Tannir NM; Slack RS; Babaian KN; Jonasch E; Pagliaro LC; Compton Z; Tamboli P; Sircar K; Pisters LL; Matin SF; Karam JA
Urol Oncol; 2015 Apr; 33(4):166.e21-9. PubMed ID: 25700975
[TBL] [Abstract][Full Text] [Related]
56. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
[TBL] [Abstract][Full Text] [Related]
57. Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes.
Ged Y; Chen YB; Knezevic A; Casuscelli J; Redzematovic A; DiNatale RG; Carlo MI; Lee CH; Feldman DR; Patil S; Hakimi AA; Russo P; Motzer RJ; Voss MH
Clin Genitourin Cancer; 2019 Jun; 17(3):e678-e688. PubMed ID: 31036466
[TBL] [Abstract][Full Text] [Related]
58. Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme.
Ohashi R; Martignoni G; Hartmann A; Caliò A; Segala D; Stöhr C; Wach S; Erlmeier F; Weichert W; Autenrieth M; Schraml P; Rupp NJ; Ohe C; Otsuki Y; Kawasaki T; Kobayashi H; Kobayashi K; Miyazaki T; Shibuya H; Usuda H; Umezu H; Fujishima F; Furusato B; Osakabe M; Sugai T; Kuroda N; Tsuzuki T; Nagashima Y; Ajioka Y; Moch H
Virchows Arch; 2020 Mar; 476(3):409-418. PubMed ID: 31760491
[TBL] [Abstract][Full Text] [Related]
59. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.
Santoni M; Conti A; Partelli S; Porta C; Sternberg CN; Procopio G; Bracarda S; Basso U; De Giorgi U; Derosa L; Rizzo M; Ortega C; Massari F; Iacovelli R; Milella M; Di Lorenzo G; Buti S; Cerbone L; Burattini L; Montironi R; Santini D; Falconi M; Cascinu S
Ann Surg Oncol; 2015; 22(6):2094-100. PubMed ID: 25472645
[TBL] [Abstract][Full Text] [Related]
60. Impact of Microvascular Invasion and Tumor Necrosis on the Prognosis of Korean Patients with pT1b Renal Cell Carcinoma.
Kwon SY; Lee JN; Kim BS; Ko YH; Song PH; Kim HT; Kim TH; Yoo ES; Choi GS; Kim BW; Kwon TG
Urol Int; 2015; 95(1):65-71. PubMed ID: 25413438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
